TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Total Lymphocyte Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Modified Laitinen's pain questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stratford's back pain functional scale (BPFS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: sleep disorders and problems
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Area Under Plasma Lorlatinib Concentration-Time Curve (AUC24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Maximal Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed cognitive deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Delayed functional deterioration
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient preference weights for side effect reduction
Endpoint domain: Adverse events/effects
Primary endpoint: Two-year progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in CRP value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Development of proliferative diabetic retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Change From Baseline in PR-PCSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hypoglycemic excursions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neurocognitive Functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pediatric Recommended Phase 2 Dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of cytokines/chemokines/proteins with CPPS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional capability of transplanted hepatocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Cohen-Mansfield Agitation Inventory Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Caregiver-reported BRIEF Global Executive Composite T Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Go-No-Go Signal Detection Parameter D-prime
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: upper respiratory infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Right ventricular end diastolic diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in Autism Diagnostic Observation Schedule (ADOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient-reported GI symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Scar measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patient and Observer Scar Assessment Scale (Subject facing)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patient and Observer Scar Assessment Scale (Non-Subject facing)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of episodes of fecal incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: (18)F-FDG uptake in supraclavicular brown adipose tissue (SUVmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Secondary infection with influenza
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of circulating tumor DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plasma concentrations of kinase inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Imiquimod 5% cream
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: prevalence of comorbid conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of concomitant medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Computerized Visual Field
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Biofilm-protected Bacteria Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Recovery time from moderate neuromuscular block to a TOF ratio more than 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical outcome (complications)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-hospital Costs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Patella lateral tilt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of COVID-19 in cancer patients using interferon-alpha as prophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of death and/or need for invasive or non-invasive ventilation
Endpoint domain: Mortality/survival
Primary endpoint: Time to clinical improvement or discharge from hospital
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Decline in Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Insulin Maximum Observed Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Patient-assessed quality adjusted life years
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change on pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preterm Infants' Sleep - Actigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preterm Infants' Health - Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of catheter related blood stream infections (CRBSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Expression of TUBB3 and BRCA1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: I-FABP levels at diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: I-FABP levels during remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of olaparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant toxicities and adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of chronic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Global Cognitive Functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time taken for normalisation of respiratory rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time taken for normalisation of Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken for oxygen saturation to normalise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in type-1 collagen carboxy telopeptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ambulatory Activity Profile
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improved Speech Intelligibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change from study baseline FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lake Louise Score (LLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Vibration sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Monofilament test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Necrotizing enterocolitis by modified Bell criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mortality in percentage
Endpoint domain: Mortality/survival
Primary endpoint: Western Ontario Rotator Cuff index (WORC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Degree of suppression of nickel-induced contact hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: level of serum mitochondrial DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent laryngeal nerve paralysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CO2 elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal pain level during the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of pH testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter and intra observer variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disease exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgery rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cmax: Maximum Observed Plasma Concentration for Lemborexant and Its Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-8h): Area Under the Concentration-time Curve From Zero Time to 8 Hours Postdose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in dryness, fatigue, and pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of duodenal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in transient intermittent hypoxemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-poliovirus Types 1, 2 and 3 Antibody Titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroprotected Subjects Against Polio Types 1, 2 and 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seropositive Subjects for Anti-D and Anti-T Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Uptake of long-acting reversible contraception (LARC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mYPAS Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: End-tidal Carbon Dioxide (ETCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants Choosing Hormonal Contraceptive Method
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Seroconversion rates to HPV-16 and HPV-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of Local Residual Neoplasia (LRN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety profile of NUC-1031
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Average Daily Steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of volume of the ridge from baseline to 4 months post-op
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Vertical dimension of the ridge from baseline to 4 months post-op
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Horizontal dimension of the ridge from baseline to 4 months post-op
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Soft tissue from baseline to 4 months post-op
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: medical morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: developmental progress
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patients' experience of self-administration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of Bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in psychosocial consequences
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall Lip Fullness Scale Responder Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of corneal epithelium regeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mood symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: late loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1st trimester miscarriage
Endpoint domain: Mortality/survival
Primary endpoint: Percent reduction in PVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mobilization Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Recurring Disease
Endpoint domain: Adverse events/effects
Primary endpoint: Hospitalization Time
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Risk of subsequent acute pancreatitis episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants That Engrafted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants That Had Full Donor Chimerism at Day 60
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients in Each Category of Hospitalizations by Study Visit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Ultrasound derived diameters of radial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incremental recovery for Factor IX
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ultrasonographic fluid assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12 month survival
Endpoint domain: Mortality/survival
Primary endpoint: McMaster Family Assessment Device (FAD)
Endpoint domain: Life impact
Endpoint subdomain: Family functioning
Primary endpoint: Percent Reduction in Urinary Incontinence Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in total tic severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: far-near deviation difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxidative metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Forced expiratory volume in one second (FEV1) percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Deviation value between scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of intravenous pantoprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DFS rate
Endpoint domain: Mortality/survival
Primary endpoint: Quality of Life (QLV)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Subjective Reinforcement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Correct Use of the Method
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Chosen Contraceptive Method After Counseling
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Severity of Crow's feet lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of Japanese Orthopaedic Association Score (JOA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Neck Disability Index (NDI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of Sagittal Lordosis Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Recovery Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to first severe prejudicial event
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Liver Fat Content on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic INR range (TTR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 9-month progression-free survival (PFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Cortical Evoked Potential (CEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Predictive value of FLIR ONE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygenated Hemoglobin levels in the prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamic parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area of reepithelialization of corneal epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-Reported Suicide Attempts
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Hospitalizations and Behavioral Health Treatment
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Major Adverse Event Composite
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of responders in the Device vs. the Surgery group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suicidal Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in albumin corrected calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in ionized calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of gait parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Confidence in Ability to Perform Teamwork
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in airway compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in airway resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in partial oxygen pressure (PaO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall response rate of an unirradiated lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With the Usage of Doripenem as Per the Approved Indication
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants With Different Mode of Usage of Doripenem
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Duration of Antibiotic Therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants With Acute Physiology and Chronic Health Evaluation II (APACHE II) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial Progenitor Cells analysis using antibodies for inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in Daily Oral Corticosteroid Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of patients with undetectable hepatitis b virus DNA after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: The changes of glomerular filtration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: The changes of bone mineral density in lumbar spine and hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants With FVIII Inhibitor Development
Endpoint domain: Adverse events/effects
Primary endpoint: Success Rate of Immune Tolerance Induction (ITI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality rate at Day 28
Endpoint domain: Mortality/survival